SciSparc Shares Rise On Initiating Clinical Trial Of SCI-210
SciSparc Ltd. (SPRC) shares surged by 51% on Friday following the announcement of the initiation of a clinical trial at Soroka Medical Center in Israel. The trial will be conducted using the company's proprietary therapy, SCI-210, which is aimed at easing the symptoms of autism spectrum disorder (ASD) in children.